Your current web browser is outdated. For best viewing experience, please consider upgrading to the latest version.

Contact

Send a question or comment using the form below. This message may be routed through support staff.

Email Article

ERROR
Main Error Mesage Here
More detailed message would go here to provide context for the user and how to proceed
ERROR
Main Error Mesage Here
More detailed message would go here to provide context for the user and how to proceed
search DONATE
Close Nav

Randall Lutter Joins Manhattan Institute as Senior Fellow in Health Policy

back to top
press release

Randall Lutter Joins Manhattan Institute as Senior Fellow in Health Policy

November 18, 2020

NEW YORK, NY –  The Manhattan Institute is pleased to announce that Randall Lutter has joined the Institute as a senior fellow on its health policy team.

Lutter, former senior science and regulatory advisor to FDA commissioners Scott Gottlieb and Stephen Hahn, will focus on drug policy, medical innovation, and regulation.

“The Manhattan Institute is committed to the ideal of a health care system that utilizes technology, innovation, and new business models to provide accessible, high-quality care at affordable prices. We are thrilled that Randall Lutter will bring his decades of expertise and knowledge to our team to help us advance that mission,” said Brandon Fuller, vice president of research and publications at the Manhattan Institute. “Lutter’s work on pharmaceutical markets, regulatory policy, and our current health crisis, couldn’t be more needed at this time.” 

In addition to his work for the FDA, Lutter is a veteran of the Council of Economic Advisers and OMB, serving under presidents Bill Clinton, George W. Bush, Barack Obama, and Donald Trump. Lutter has had a distinguished career outside of government as well, joining the faculty of the University of Virginia between his stints in the Obama and Trump administrations and spending time as a resident fellow at the American Enterprise Institute. Most recently, Lutter led FDA projects involving pharmaceutical competition and drug pricing, the regulation of tobacco products, and the surveillance of medical product supply chains disrupted by Covid-19.

“I am very excited to join the Manhattan Institute to write about policies to use market efficiencies to deliver medical innovations that offer meaningful improvements in the health of Americans—topics that seem to be of extraordinary importance as we all look forward to safe and effective vaccines and therapeutics for Covid-19,” added Lutter. “I also look forward to writing on regulation generally since the role of the federal government in overseeing details of American life has only become more contentious in recent years.” 

For more information on the Manhattan Institute’s health policy research and commentary, visit us here.

Contact

Nora Kenney

Senior Press Officer

(646) 839-3313

nkenney@manhattan-institute.org

Saved!
Close